This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Columvi (glofitamab-gxbm)
General Description:
Columvi (glofitamab-gxbm) is a bispecific antibody that targets both CD20 on B-cells and CD3 on T-cells. It is prescribed for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adult patients.
By binding to CD20 and CD3, Columvi helps activate T-cells to recognize and eliminate cancerous B-cells, offering an advanced treatment option for patients who have not responded to previous therapies.
Columvi was approved by the U.S. Food and Drug Administration (FDA) in June 2023 and is also authorized in several other global markets.
Disease Indications:
Lymphoma (Diffuse Large B-Cell Lymphoma – DLBCL)
Manufacturer:
ROCHE PHARMA AG
Usage:
Intravenous
Medicine Approved by:
• European Medicines Agency (EMA)
• Food and Drug Administration (FDA)
Package:
• Single-dose vial × 2.5 mg/2.5 mL
• Single-dose vial × 10 mg/10 mL
Shipping:
Cold Chain Shipping
Certain medicinal ingredients are sensitive to heat, light, and handling. To ensure product integrity, Columvi is shipped under strict cold chain conditions using specialized medical couriers with temperature-controlled packaging and vehicles.
This helps maintain the medicine’s stability and effectiveness, though cold chain delivery may be slightly more expensive than standard shipping.
How to Access Columvi (glofitamab-gxbm) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Columvi (glofitamab-gxbm) is not yet approved or commercially available in India, MitoGENE can assist you in accessing it legally through the Named Patient Program (NPP). Here’s how the process works:
